ClinicalTrials.gg
RecruitingNCT07387081Updated Feb 4, 2026

Phase II Study of LM-24C5

A Phase 2 interventional study of LM-24C5 and LM-24C5 in Advanced Solid Tumor Cancer, sponsored by LaNova Medicines Limited. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor

02

Conditions studied

  • Advanced Solid Tumor Cancer
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing to participate in the study and sign the form (ICF) prior to any procedure.
  2. Aged 18-80 years old (including boundary values) , male or female.
  3. (ECOG) performance status of 0-1.
  4. ≥ 3 months.
  5. Subjects must have histological or cytological confirmation of recurrent or advanced solid tumors, or currently lack or are intolerant of, standard therapy.
  6. CEACAM5-positive subjects.
  7. At least one evaluable lesion.
  8. Subjects must show appropriate organ and marrow function inlaboratory examinations within 7 days prior to the first dose.
  9. Subjects who can communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of other within 5 years prior to first dosing of LM-24C5, excluding cured squamous cell carcinoma of the skin, basal cell carcinoma, non-muscle-invasive bladder cancer, or localized low-risk prostate cancer, carcinoma in situ of the cervix/breast, and other malignancies deemed by the investigator to potentially benefit from participation in this study.
  2. Subjects who have received other anti-tumor treatments before the first dosing of LM-24C5.
  3. Previous immunotherapy and grade ≥3 irAE or grade ≥2 immune-related myocarditis.
  4. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of v5.0.
  5. Present peripheral sensory or motor neuropathy ≥ grade 2.
  6. Subjects with uncontrolled pain.
  7. Subjects with symptomatic and untreated central nervous system , and/or meningeal metastases.
  8. Subjects who have uncontrollable third space effusion.
  9. Previously received targeted therapy for same target.
  10. . Use of any within 28 days prior to 1st dosing of IMP.
  11. Subjects with current or previous interstitial lung diseases or pneumonia requiring oral or intravenous for therapy.
  12. Subjects on anticoagulants, such as heparin and vitamin K antagonists.
  13. Clinically uncontrollable persistent recurrent vomiting.
  14. Uncontrollable/severe gastrointestinal bleeding, ulceration or diarrhea within 28 days prior to first dose of IMP.
  15. Subjects who received major surgery or interventional treatment within 28 days prior to the first dosing of IMP.
  16. Subjects who have severe cardiovascular disease.
  17. Subjects who have uncontrolled or severe illness.
  18. Subjects who take systemic corticosteroids (> 10 mg daily prednisone equivalents) or other systemic medications within 2 weeks prior to the first dosing of IMP.
  19. Subjects with a known history of diseases.
  20. Subjects who have a history of immunodeficiency disease.
  21. Subjects with infection, active or infection.
  22. female who have positive results in pregnancy. test within 7 days before the first dose or are lactating.
  23. Subject who have a known psychiatric diseases or disorders that may affect compliance with the trial.
  24. Subject who is judged as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    LM-24C5 in combination with anti-tumor therapies

    Drug: LM-24C5

  • Experimental
    LM-24C5 in combination with other anti-tumor therapies

    Drug: LM-24C5

Interventions

  • DrugLM-24C5

    Q2W Administered intravenously Drug: Penpulimab Q2W Administered intravenously Drug: Docetaxel Q3W Administered intravenously

  • DrugLM-24C5

    Q2W Administered intravenously Drug: Penpulimab Q2W Administered intravenously Drug:Trifluridine and Tipiracil Hydrochloride Tablets BID,Oral Administration Drug:Bevacizumab Injection Q2W Administered intravenously

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate

    Time frame: 110weeks

Secondary outcomes

  1. Anti-tumor Activity

    Based on RECIST v1.1, evaluated progression-free survival (PFS), duration of response (DOR), disease control rate (DCR = CR + PR + SD), and change in target lesions relative to baseline; overall survival (OS).

    Time frame: 110weeks

  2. PK Parameter(AUClast)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  3. Immunogenicity of LM-24C5

    ADA、Nab

    Time frame: baseline and 110 weeks

  4. Correlation between CEACAM5 and/or PD-L1 expression levels and treatment efficacy.

    Correlation between CEACAM5 and/or PD-L1 expression levels and treatment efficacy.

    Time frame: baseline and 110 weeks

  5. PK Parameter(AUCtau)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  6. PK Parameter(Cmax)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  7. PK Parameter(Tmax)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  8. PK Parameter(T1/2)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  9. PK Parameter(ss)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  10. PK Parameter(Cmin)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  11. PK Parameter(CLss)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  12. PK Parameter(Vss)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  13. PK Parameter(Rac)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  14. PK Parameter(AUC)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  15. PK Parameter(Cmax)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

  16. PK Parameter(DF)

    Including but not limited to AUClast, AUCtau, Cmax, Tmax, T1/2, Cmax, ss, Cmin, ss, CLss, Vss, Rac, AUC, Rac, Rac, Cmax, DF, etc.

    Time frame: baseline and 110 weeks

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for May 2028, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Feb 4, 2026
StartActual
Dec 15, 2025
Primary completionEst.
May 21, 2028
CompletionEst.
Oct 25, 2028
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07387081
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Dec 15, 2025
Primary completion
May 21, 2028 (estimated)
Completion
Oct 25, 2028 (estimated)
Last update
Feb 4, 2026

Study contacts

Mengmeng Liu
Contact
mengmengliu@lanovamed.com
+8613918118040
Paul Kong
Contact
paulkong@lanovamed.com
+8613564682439

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion